Intra Cellular Therapies, Inc. ‘s ITCI shares shot up 86.9% and hit a 52 week high of $49.75 on Sep 16 after the company announced encouraging data from its first phase III study on ITI 007 for the treatment
Intra-Cellular Up on Positive Data from Schizophrenia Study
